INTRODUCTION

In 1994, Rosqvist and colleagues proposed a model for a specialized molecular machine in Yersinia closely related to the bacterial flagellar apparatus that has the capacity to secrete bacterial proteins into the extrabacterial environment (125). This bacterial type III secretion system (T3SS) is of special interest to those studying host-pathogen interactions because, by utilizing this system, bacteria are able to directly inject bacterial proteins called effectors into host cells across bacterial and host membranes, where they can manipulate host cell function.

Homologous T3SSs have been described for many gram-negative bacterial species, including pathogens (predominantly) and commensals of mammals, plants, and insects (for some examples, see Table 1) (reviewed in reference 149).

The T3SS is a complex structure composed of several subunits, which in turn are made up of approximately 20 bacterial proteins (Fig. 1). The proteins that make up the T3SS apparatus are termed structural proteins. Additional proteins called "translocators" serve the function of translocating another set of proteins into the host cell cytoplasm. The translocated proteins are termed "effectors," since they are the virulence fac-


tors that effect the changes in the host cells, allowing the invading pathogen to colonize, multiply, and in some cases chronically persist in the host. The structural components of the T3SS and the process of translocation are expertly reviewed by Ghosh (40). Briefly, the T3SS apparatus consists of two rings that provide a continuous path across the inner and outer membranes, including the peptidoglycan layer. The inner membrane ring is the larger of the two coaxial rings, and protein components that make up the inner ring have been identified for a number of bacteria. The outer membrane ring is composed of the secretin protein family, which is also known to be involved in type 2 secretion and in the assembly of type IV bacterial pili. A needle-like structure associates with the outer membrane ring and projects from the bacterial surface. It varies in length among the different pathogens and, in the case of pathogenic Escherichia coli, is extended by the addition of filaments that are thought to facilitate attachment to the host cells through the thick glycocalyx layer. Effectors are thought to be transported through the hollow tube-like needle into the host cell through the pores formed in the host cell membrane by the translocator proteins. Translocators are usually conserved among the different pathogens possessing a T3SS and show functional complementarity for secretion and translocation, whereas the effectors are most often distinct, having unique functions suited to a particular pathogen's virulence strategy. However, effector homologues also exist among different T3SS-possessing bacteria.
<table>
<thead>
<tr>
<th>Pathogen</th>
<th>T3SS components</th>
<th>Hosts</th>
<th>Relationship with hosts</th>
<th>Diseases caused by agent</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yersinia species (Y. pestis, Y. enterocolitica, Y. pseudotuberculosis)</strong></td>
<td>Ysc injectisome, YopB, YopD, LcrV, YopH, -E, -T, and -O and YpkA, -P/J, and -M</td>
<td>Humans, cattle, rodents, fleas (Y. pestis)</td>
<td>Pathogen</td>
<td>Plague (bubonic, pneumonic, and septicemic) (Y. pestis), enterocolitis and mesenteric lymphadenitis (Y. enterocolitica and Y. pseudotuberculosis)</td>
</tr>
<tr>
<td><strong>Salmonella enterica serovars</strong> (Typhimurium, Typhi, Paratyphi, Sendai, Dublin, and Choleraesuis)</td>
<td>SPI1, PrgK, PrgH, InvG (ring base), Prgl (needle), and SipBC/D (putative translocators); SPI2, Ssa proteins (apparatus), Ssc proteins (effector chaperones), SsrAB (regulators), and SseB/C/D (translocators)</td>
<td>Humans, rodents, chickens, cows, and pigs</td>
<td>Pathogen (in humans, rodents, cows, and pigs), innocuous carriage (in chickens and some human cases)</td>
<td>Enterocolitis in humans and typhoid-like disease in mice (serovar Typhimurium), enteric fever in humans (serovars Typhi, Paratyphi, and Sendai), intestinal inflammation and bacteremia in cows (serovar Dublin), septicemia in pigs (serovar Choleraesuis)</td>
</tr>
<tr>
<td><strong>EPEC/EHEC</strong></td>
<td>EspA/B/D (translocators)</td>
<td>Humans, cows, calves</td>
<td>Pathogen (in humans and calves), innocuous carriage (in cows)</td>
<td>Intestinal inflammation and bloody diarrhea (EPEC/EHEC), possibility of renal failure and septic shock (EHEC)</td>
</tr>
<tr>
<td><strong>Shigella species (S. dysenteriae, S. flexneri, S. boydii, and S. sonnei/multiple serotypes)</strong></td>
<td>Mxi/Spa (apparatus), IpaBC (translocators), IpgC (IpaBC chaperone)</td>
<td>Humans (only known reservoir)</td>
<td>Pathogen</td>
<td>Bacillary dysentery (shigellosis), sporadic dysentery pandemics (S. dysenteriae)</td>
</tr>
<tr>
<td><strong>Bordetella species (B. pertussis, B. parapertussis, and B. bronchiseptica)</strong></td>
<td>BopB, BopD (potential translocators)</td>
<td>Humans, dogs, pigs</td>
<td>Pathogen</td>
<td>Whooping cough (B. pertussis and B. parapertussis [milder with B. parapertussis]), kennel cough in dogs, atrophic rhinitis in swine, possible respiratory illness in humans (B. bronchiseptica)</td>
</tr>
<tr>
<td><strong>Pseudomonas aeruginosa</strong></td>
<td>PopB and PopD (translocators), PcvV, SpcU (chaperon for ExoU)</td>
<td>ExoS, ExoT, ExoU, ExoY</td>
<td>Part of normal flora in up to 20% of humans, common in the environment</td>
<td>Opportunistic and nosocomial pathogen</td>
</tr>
<tr>
<td><strong>Burkholderia pseudomallei</strong></td>
<td>T3SS-1, T3SS-2, T3SS-3 (Bsa)</td>
<td>BopAB (putative), BopE (T3SS-5), VP1680 (T3SS1), VopA (T3SS2)</td>
<td>Environmental isolate, humans</td>
<td>Human pathogen</td>
</tr>
<tr>
<td><strong>Vibrio parahaemolyticus, V. cholerae</strong></td>
<td>T3SS1 (V. parahaemolyticus), T3SS2 (V. parahaemolyticus and V. cholerae)</td>
<td>IncA and additional Inc proteins, Cptn0909, Cptn1020</td>
<td>Obligate intracellular pathogens, infectious bodies found in the environment</td>
<td>Human pathogens</td>
</tr>
<tr>
<td><strong>Chlamydia species</strong></td>
<td>YscN (ATPase), LcrH1 and -2 and SyeE (chaperones), LcrE (structural &quot;lid&quot;)</td>
<td>(C. trachomatis and C. pneumoniae), bird pathogen (C. psittaci)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Also carry the T3SS components BopN and Bsp22 (whose functions are unknown).
The clinical spectrum of disease caused by T3SS-containing pathogens is remarkably broad. Infection with enteropathogenic and enterohemorrhagic *E. coli* (EPEC and EHEC, respectively), *Shigella*, *Salmonella*, and *Yersinia* species results in intestinal disease. *Yersinia pestis* is the causative agent of plague. *Salmonella* serovar Typhi causes enteric fever. *Bordetella* causes whooping cough, while the opportunistic pathogen *Pseudomonas aeruginosa* can cause a variety of problems, including pneumonia, urinary tract infection, wound infection, septicemia, and endocarditis. *Chlamydia trachomatis* is a common sexually transmitted organism, and *Chlamydia pneumoniae* causes pneumonia and has been implicated in atherosclerotic disease of blood vessels. *Burkholderia pseudomallei* causes community-acquired bacteremia and pneumonia. Whether by a direct toxic mechanism or through induction of self-damaging host responses, the virulence of all of these bacteria utilizes T3SSs. Clearly, T3SSs are not restricted to a specific pathogen, tissue, host environment, clinical disease spectrum, or patient population. Here we explore how the activity of the T3SS has been adapted by these human pathogens to execute their virulence programs.

**ADHERENCE, INVASION, AND COLONIZATION**

To promote adherence, invasion, and colonization, many known bacterial, viral, and eukaryotic pathogens establish intimate interactions with the cytoskeletons of infected host cells. The maintenance of the host cell cytoskeleton is crucial to many aspects of normal host physiology, such as the preservation of cellular architecture, highly selective epithelial permeability, vesicular transport, and phagocytosis. Infections with T3SS-containing pathogens often disrupt these structures and processes.

A common theme of T3SS-dependent virulence is the subversion of the host cytoskeleton through direct or indirect manipulation of small Rho GTPases or direct interactions with filamentous (F-actin) or globular (G-actin) actin. Rho GTPases are central in regulating cytoskeletal functions (121). They are activated by guanine nucleotide exchange factors (GEFs) and down-regulated by GTPase-activating proteins (GAPs). Activated Rho GTPases recruit proteins, such as N-WASP and WAVE-2, which drive actin nucleation through the activity of the Arp2/3 complex. T3SS-containing pathogens also manipulate the levels of cellular phosphoinositides that anchor the actin cytoskeleton to the plasma membrane and activate GEFs.

**Adherence and Invasion of Host Cells**

The hallmark of EPEC- and EHEC-induced intestinal pathology is the attaching and effacing (A/E) lesion, whose formation depends on a T3SS encoded within the loci of enterocyte effacement (LEE) and the interplay of many T3SS effectors.

Following intimate attachment of the bacteria to the intestinal epithelium, the brush border microvilli are disrupted (effacement), and the bacteria promote formation of actin pedestals that elevate the pathogen above the intestinal epithelium (75). To attach to the enterocytes, EPEC and EHEC utilize their T3SSs to inject the translocated intimin receptor (Tir) into the host cell (33), where it inserts into the host cell membrane and binds to the bacterial outer membrane protein intimin. Binding of intimin to Tir induces Tir clustering, initiating a cascade of signaling events that leads to actin polymerization and pedestal formation (13). This ultimately results in the formation of the A/E lesion. EPEC Tir is tyrosine phosphorylated to recruit the Arp2/3 complex and drive actin polymerization (12, 117), whereas EHEC Tir is not phosphorylated but, rather, relies on an additional T3SS effector, TccP/EspFU, for Arp2/3 recruitment (11, 37). Successful pedestal formation requires down-regulation of filopodia, which form in response to EPEC/EHEC infection, as well as disruption of the host microtubule network. The T3SS effectors Map (mitochondrion-associated protein) (69), Tir (64), EspH (153), EspG, and EspG2 (14) mediate these processes. This multifaceted approach allows A/E pathogens to coordinate the formation of A/E lesions and actin pedestals, providing them with a unique niche in the intestine of the infected host.

*Salmonella* and *Shigella* promote their own uptake into nonphagocytic cells by targeting several signaling pathways that converge to induce the formation of transient actin-rich membrane ruffles that engulf the infecting bacterium (44, 134). This allows them to reside and replicate in a privileged site, minimizing exposure to the immune system of the host. *Salmonella* encodes two T3SSs on two *Salmonella* pathogenicity islands (SPI1 and -2). SPI1 is necessary for invasion into the nonphagocytic cells of the intestinal epithelium. Two SPI1-encoded T3SS effectors, SipA (95, 169) and SipC (17, 51), cooperate to stabilize and nucleate actin, respectively, but are...
not sufficient to induce formation of the membrane ruffles necessary for *Salmonella* uptake into nonphagocytic cells (134). Additional SPI1 effectors activate Cdc42, Rac, and RhoG (Rho GTPases) by either mimicking the function of their cognate GEFs (SopE and SopE2) (168) or generating activating second messengers (SopB/SigD, a phosphatidylinositol phosphatase) (134). Another effect of SopB/SigD-mediated depletion of phosphatidylinositol 4,5-bisphosphate in the invaginating regions of the host cell membrane is increased malleability of the host cell membrane, which facilitates remodeling associated with *Salmonella* entry (145). Modulation of vesicular trafficking seems to involve SopB modulation of phosphoinositide metabolism (54). Once *Salmonella* is engulfed, the host cells need to return to a somewhat normal state. The normalization process is facilitated by SptP, a T3SS-1 effector with GAP activity that inactivates Rac and Cdc42 (44). The concerted efforts of the SPI1 effectors SipA, SipC, SopB/SigD, SopE, SopE2, and SptP result in the engulfment of *Salmonella* by the host cell.

Unlike *Salmonella*, *Shigella* does not infect the apical surface of the intestinal epithelium but, rather, gains entry into the submucosa by infecting M cells and macrophages. After inducing apoptosis in infected macrophages, it is released at the basolateral surface of the intestinal epithelium, where it invades and ultimately spreads intra- and intercellularly (58). Entry into epithelial cells is followed by escape from the phagosome; both are dependent on a T3SS invasion complex comprised of IpaB and IpaC (96), which translocates T3SS effectors into the host cell. In a process similar to *Salmonella* invasion, *Shigella* T3SS effectors act in concert to activate or mimic the action of Rho GTPases (IpaC [148], IpgB1 [109], and IpgB2 [3]), induce inositol fluxes (IpgD [92]), and destabilize microtubules (VirA [163]). These actions culminate in *Shigella* entry into the host cell. Following entry, the normal cellular architecture is restored, likely through the action of IpaA, which promotes F-actin depolymerization (9).

Hence, *Shigella* invasion of epithelial cells proceeds through the basolateral side of the epithelium, is mediated by the Ipa complex, IpaD, IpgB1, and IpgB2, and is made more efficient by IpaA and VirA. Once inside the host cell, *Shigella* escapes from the phagolysosome through the action of T3SS effectors IpaB (57) and IpaH7.8 (28). Although *Shigella* is a nonmotile pathogen, it utilizes the host cytoskeleton to induce the formation of actin tails that propel it within and between the cells. The T3SS effector OspE2 appears to preserve cellular architecture and, in this manner, to facilitate *Shigella* intercellular spread. In its absence, *Shigella*-infected cells exhibit rounding, which reduces the efficiency of actin-based motility (99). VirA was recently demonstrated to have an additional function as a cysteine protease digesting alpha-tubulin, thus degrading the microtubule network, to promote *Shigella* motility (162). The microtubule network in the host cell cytosol inhibits *Shigella* movement, and VirA cysteine protease activity creates clear paths in the microtubule jungle along which *Shigella* can move. Consequently, the concerted actions of multiple *Shigella* T3SS effectors facilitate its invasion of the host cell and promote its further dissemination.

**Intracellular Survival and Subversion of Cellular Trafficking Processes**

Once *Salmonella* is engulfed, the SPI2-encoded T3SS is activated and interferes with phagosome maturation, resulting in the formation of a specialized *Salmonella*-containing vacuole (SCV), where *Salmonella* resides during intracellular survival and replication (reviewed in reference 80). SCV formation proceeds through a number of steps, including interference with the endocytic pathway, which prevents the delivery of hydrolytic enzymes to the SCV; transport of the SCV to the perinuclear region; and development of *Salmonella*-induced filaments (SIFs) (80). All of these events proceed through *Salmonella* interference with many cellular processes and culminate in the survival, multiplication, and spread of *Salmonella*. The SPI2-encoded T3SS is essential to orchestrate SCV biogenesis and *Salmonella*’s intracellular survival.

One of the features of intracellular *Salmonella* pathogenesis is the assembly of an actin coat around intracellular bacteria, which may promote SCV fusion with actin-containing or actin-propelled vesicles and may also exert a protective effect on the SCV by preventing its fusion with unfavorable compartments (44). The assembly of the F-actin coat is dependent on the SPI2-encoded T3SS, specifically the effectors SseB, -C, and D as well as SpIC (164).

SCVs are transported along the microtubules to the microtubule organizing center located in the perinuclear region (80). From this position, *Salmonella* modulates cellular trafficking processes in a SPI2 T3SS-dependent manner, thus gaining access to a supply of nutrients and membrane materials for maintenance of SCVs and formation of a tubular network of membrane structures called SIFs that connect the individual SCVs in the infected cell. Dependent on SseF and SseG, intracellular *Salmonella* redirects the Golgi apparatus-derived exocytic transport vehicles—which are normally targeted to the cytoplasmic membrane—to the SCV instead (81). The subversion of Golgi apparatus-derived vesicles is crucial for efficient replication of SCV-bound *Salmonella*, as disruption of the Golgi network was shown to strongly inhibit *Salmonella* intracellular growth (80).

A number of *Salmonella* SPI2 effectors are involved in the proper positioning and maintenance of the SCV. SifA modulates the association of SCV with the kinesin motor protein, potentially preventing excessive formation of outgoing vesicles and resultant SCV disruption (8). SseG and SseF are additional SPI2 effectors required for SCV biogenesis and potentially for perinuclear localization of SCV (1, 82). *Salmonella* lacking SseF is deficient in the ability to recruit the motor protein dynein to the SCV, and SseF appears to partner with SseG to promote dynein recruitment and SCV transport along the microtubules. The concerted function of SifA, SseF, and SseG has the effect of differentially recruiting the motor proteins of the microtubules to the SCV to promote proper SCV positioning.

SifA is required for the formation of SIFs, although the exact mechanism involved in SIF biogenesis is still not known (74). SPI2 effectors SseF and -G (82, 83), as well as PipB2 (73) and SopD2 (65), have also been shown to have a role in SIF formation.

In sum, by interfering with multiple cellular processes via its
SPI1- and SPI2-encoded T3SSs, Salmonella provides itself with a convenient niche for intracellular survival, replication, and subsequent spread. T3SS-assisted colonization strategies of various pathogens demonstrate that T3SSs are central to their virulence. Using T3SSs, pathogens undertake the first step of pathogenesis: they establish a convenient and safe niche inside the host from where they can interfere with various physiological processes, as described below.

**TYPE III SECRETION IN CYTOTOXICITY**

The T3SS-dependent invasion, survival, and persistence of pathogens within the host are invariably associated with damage to host tissues. T3SS-associated damage takes a number of forms, including direct cytotoxicity associated with the induction of apoptosis or necrosis or tissue damage associated with the disruption of tissue barriers. These mechanisms promote pathological outcomes, such as diarrhea or inflammation.

**Direct Cytotoxicity**

Cell death is an important mediator of tissue destruction and pathology in a variety of diseases. The destruction of cells may be sufficient to cause tissue/organ dysfunction alone, it may enable pathogens to disseminate or breach barriers, or it may induce an inflammatory response which is the root of disease production. T3SSs have been implicated in a variety of these pathogenic mechanisms.

One of the hallmarks of Pseudomonas infection is epithelial injury in infected lungs. Lung pathology in murine infection models requires a functional cytotoxin, ExoU, which is translocated by the Pseudomonas T3SS (30). Cytotoxicity induced by ExoU occurs independently of other T3SS effectors and appears to be due to phospholipase activity. The translocation of active ExoU results in destabilization and destruction of intracellular membranes. This destabilization results in necrosis and correlates with a variety of clinical parameters of disease in infection models, including transudation into alveoli, interstitial pathology, and mortality (29, 30, 133).

In 2003, following genome sequencing of Vibrio parahaemolyticus, two T3SSs were identified (91). Each of the two V. parahaemolyticus chromosomes encodes one T3SS, which were therefore designated T3SS1 and T3SS2. This finding was thought to account for the differences in clinical manifestations of V. parahaemolyticus and Vibrio cholerae infections: V. cholerae generally causes noninflammatory secretory diarrhea, whereas the clinical features of V. parahaemolyticus infection commonly include inflammatory diarrhea and even systemic spread. Vibrio cholerae is subdivided into a number of serotypes, among which O1 and O139 are the most common clinical isolates and are also those responsible for the seven cholera pandemics documented since 1861 (25). However, some of the non-O1, non-O139 V. cholerae species might be much more dependent on the T3SS and in this way related to those of other T3SS-carrying enteric pathogens than was previously thought.

The genome organization of V. parahaemolyticus is very similar to that observed for Yersinia species, and a number of genes homologous to Yersinia T3SS effectors have been identified (114). When the functional contribution of each T3SS to the manifestations of V. parahaemolyticus infection was analyzed, it was observed that T3SS1 was key for the in vitro cytotoxicity of V. parahaemolyticus, whereas T3SS2 was dispensable for this function (114). Recently, Ono et al. (110) demonstrated that T3SS1-dependent cell death was by apoptosis and identified VP1680 as a T3SS1-translocated protein central to T3SS1-induced cytotoxicity. In contrast to cytotoxicity, enterotoxicity induced by V. parahaemolyticus appeared to be due mainly to the presence of T3SS2, as demonstrated by infections in rabbit ileal loops. Ileal loops infected with wild-type V. parahaemolyticus or T3SS1 mutant bacteria exhibited massive hemorrhage and inflammatory changes, while infection with T3SS2 mutant bacteria failed to induce these pathological changes. The differential functions of T3SS1 and T3SS2 are compatible with the observation that different effector proteins are selectively targeted for secretion by each of these secretion systems (114).

**Disruption of Epithelial TJs**

Disruption of tight junctions (TJs) is a common mechanism utilized by pathogens to promote their virulence. TJs are composed of transmembrane proteins (occludin, claudins, and junctional adhesion molecule) and cytoplasmic proteins, among them zona occludens (ZO) proteins. ZO proteins act as adaptors linking the TJ-associated proteins to each other and to the actin cytoskeleton, including the perijunctional actomyosin ring that regulates TJ permeability. Several signaling molecules localize at TJs (151), and Rho family proteins are also implicated in their assembly and maintenance (152). Diarrhea is one of the most frequent manifestations of infectious intestinal diseases, promoting the spread of the pathogen to new hosts. The disruption of TJs is an important contributor to diarrheagenesis.

T3SS-facilitated disruption of TJs was shown to be an important factor contributing to diarrhea initiation during Citrobacter rodentium infection of mice, with the T3SS effector EspF being central to the process of TJ disruption (46). Murine C. rodentium infection is a well-established model of EPEC/EHEC infections (88). EHEC, although closely related to EPEC, does not induce epithelial barrier disruption as quickly or severely as that induced by EPEC. This difference is possibly due to the fact that EHEC-induced TJ disruption is mainly regulated by U-EspF, an EspF homologue, with EspF itself playing only a minor role (158). Map and EspG, together with EspG2, are additional EPEC T3SS effectors implicated in the disruption of the intestinal epithelial barrier (23, 90, 147).

An additional mechanism employed by C. rodentium to induce diarrhea in infected mice is mislocalization of aquaporin water channels (45). Aquaporins contribute to stool dehydration, and during C. rodentium infection, they move from their normal location along the apical cell membrane to the cytoplasm, an effect which is partially dependent on EspF and...
EspG T3SS effectors. Restoration of aquaporin localization to the cell membrane is observed following recovery from infection and cessation of diarrhea.

Many cellular mechanisms underlie EPEC-mediated disruption of epithelial integrity. A cause-effect relationship can be observed in phosphorylation of myosin light chain, which results in contraction of the actomyosin ring, opening up the TJs and decreasing the transepithelial resistance.

Similar to the case with A/E pathogens, Salmonella-induced diarrhea is dependent on disruption of the intestinal epithelial barrier via the T3SS. Salmonella enterica serovar Typhimurium SPI1 T3SS effectors SipA and SopA, -B, -D, and -E2 were shown together to induce fluid accumulation in intestinal bovine loops and diarrhea in vitro and in vivo in calves (10, 120, 167). The SPI1 T3SS effector SopB/SigD is involved in modulating chloride secretory responses in infected epithelial cells (5), a possible mechanism in the induction of diarrhea by S. enterica serovar Typhimurium. Thus, SPI1, in addition to mediating Salmonella invasion of host cells, also promotes the induction of diarrhea as a consequence of disruption of the epithelial barrier.

Yersinia pseudotuberculosis was shown to bind to β1-integrins via the T3SS effector YopE, disturbing ZO-1 and occludin localization, promoting actin rearrangement, and disrupting the barrier properties of the epithelium, thereby promoting paracellular translocation of bacteria (143). It appears that disruption of TJs by Y. pseudotuberculosis is an important mechanism of transport to the basolateral side of the epithelium, from which invasion of Y. pseudotuberculosis into the epithelial layer occurs.

T3SS-mediated cytotoxicity induces multiple results, such as cell death-associated organ dysfunction, inflammatory changes, and diarrhea. All of these are important manifestations of the disease process that mediate both morbidity and mortality.

**T3SS AND HOST IMMUNITY**

In addition to physical barriers such as the intestinal epithelium, an important biological barrier to disease-causing microbial infection is the defense of the host. The evolution of the T3SS is associated almost exclusively with pathogenic organisms, and it is not surprising that T3SSs are involved in interactions with host immune responses. T3SSs have been adapted by pathogens to provoke or evade host innate immunity in a variety of ways, including the direct activation of host signaling cascades, triggering of host pattern recognition through extracellular and intracellular pattern recognition receptors (PRRs), and the suppression or evasion of innate and adaptive defenses.

**T3SSs and Pathogen Recognition by the Host**

Upon arrival in the host environment, bacteria encounter an array of PRRs that have evolved to sense pathogenic motifs (called pathogen-associated molecular patterns) and to trigger host defenses. These PRRs include extracellular receptors of the Toll-like receptor (TLR) family and the intracellular leucine-rich repeat-containing proteins of the Nod-like receptor family. These important host innate immune receptors signal the presence of bacterial motifs in privileged host environments. T3SSs are required for many pathogens to occupy or establish their host niche and are often required for indirect PRR activation (or avoidance). Agonism of these receptors also seems to occur directly by T3SS-dependent mechanisms.

Delivery of Salmonella flagellin to the basolateral intestinal epithelium is a potent inducer of epithelial inflammatory interleukin-8 (IL-8) production through the activation of the flagellin PRR TLR5 (39, 165, 166). Although flagellin is not normally secreted through the T3SS, delivery of flagellin to the basolateral membrane depends in some way on the Salmonella SPI2-encoded T3SS (89). Similarly, intracellular monomeric flagellin from Salmonella induces the activation of caspase-1 and the production of active IL-1β and IL-18 through activation of Ipaf signaling independently of TLR5 (31, 98). Either directly via the translocation of flagellin or indirectly via another mechanism, this process requires a functional SPI1 T3SS (98).

*Pseudomonas* more directly activates PRRs in a T3SS-dependent manner. The activation of both TLR2 and TLR4 is necessary for the production of a complete inflammatory response in the lungs of mice infected with *P. aeruginosa* (119). The T3SS effector ExoS activates TLR2 and TLR4/MD-2/CD14 signaling through its C and N termini, respectively (26). This activation could be induced in cultured monocytes by exogenously administered ExoS in a manner that required neither effector translocation nor ExoS internalization, suggesting that this effector can act both as a modulator of intracellular signaling (discussed below) and as a soluble secreted protein (26).

**Direct Manipulation of Host Innate Immune Signaling**

The defining feature of T3SSs is the ability to directly inject bacterial proteins into the cytosol of a host cell. *Yersinia*, *Salmonella*, and *Shigella* species have exploited this ability to manipulate the inflammatory signaling of the host. This manipulation can result in both the induction and inhibition of host innate immune signaling. Innate immune signaling in mammals involves an intricate synthesis of signaling molecules triggered by a variety of intracellular and extracellular triggers. Of particular interest for this review are two critical signaling “end points,” namely, the nuclear translocation of the cytosolic transcription factor NF-κB (nuclear factor kappa B) with the activation of inflammatory gene expression and the proteolytic cleavage and activation of the inflammatory cytokines IL-1β and IL-18 by caspase-1 (also called IL-1-converting enzyme). Both of these are potent inducers of inflammation that reflect the culmination of a variety of signaling pathways in the host. Both are also the targets of T3SS effectors.

**NF-κB**

Following the activation of a number of kinase cascades, NF-κB is liberated from its cytosolic binding partners (the IκBs), at which point it is freely translocated to the nucleus and activates the expression of inflammatory genes (reviewed in reference 66). The T3SS effectors of *Salmonella*, *Yersinia*, and *Shigella* target these signaling cascades to promote or prevent inflammatory gene expression.
The SPI1 T3SS effector SopE activates NF-κB translocation by triggering Rho GTPases (48). The result of this activation is a potent inflammatory response in epithelial cells. The initial surge of NF-κB activity initiated by SopE is subsequently dampened by another SPI1 T3SS effector, SptP. This effector antagonizes Rac-1 and Rho GTPases, resulting in the delayed diminution of inflammatory signaling (34). Notably, SPI1 T3SS effectors are also responsible for the invasive phenotype of *Salmonella*, with a consequent overlap between the proinflammatory and invasive phenotypes associated with this pathogen in some in vivo models. Furthermore, as discussed above, SPI1 T3SS effectors are somehow required for the delivery of monomeric flagellin to intracellular PRRs.

The *Shigella* T3SS effector OspG also directly inhibits NF-κB activation upon infection of host cells. OspG of *Shigella flexneri* targets the ubiquitination of IkBα, preventing it from being degraded and thereby sequestering NF-κB in the cytosol and preventing inflammatory gene induction in response to tumor necrosis factor alpha. The phenotypic result of this inhibition is decreased inflammatory severity in rabbit ileal loops that requires the OspG effector (71). An additional T3SS effector, OspF, demonstrates a highly selective inhibition of NF-κB function: OspF is a phosphatase that dephosphorylates mitogen-activated protein kinases (MAPKs), preventing epi-genetic modification of histone H3 and ultimately blocking the activation of a subset of NF-κB-responsive genes (4). This compromises the proinflammatory response and leads to a reduced recruitment of inflammatory cells to the site of infection. The *Yersinia* T3SS effector YopE/YopJ inhibits NF-κB translocation to the nucleus by inhibiting the degradation of IkBβ as well as MAPK signaling (127). YopP/YopJ was recently demonstrated to function as an acetyltransferase (102). It uses acetyl-coenzyme A to covalently modify MAPK and in this manner prevent the phosphorylation and modification of the modified protein. The *Y. pseudotuberculosis* effector YopE also inhibits NF-κB and caspase-1 activation by inactivating Rho GTPases.

In addition to the anti-inflammatory effect discussed above, inhibition of NF-κB may have a proapoptotic effect. The *Yersinia* T3SS effector YopJ and the *V. parahaemolyticus* T3SS1 effector VP1686 suppress NF-κB and, via this suppression, induce a conserved apoptotic pathway in macrophages (6, 100).

### Caspase-1

Following transcriptional activation by NF-κB, the proinflammatory cytokines IL-1β and IL-18 are activated by caspase-1-mediated cleavage. Parallel to the induction of inflammation by hijacking NF-κB signaling, T3SSs have evolved to induce caspase-1-mediated cleavage of IL-1β and IL-18, as well as caspase-1-mediated apoptosis. The *Shigella* T3SS effector IpaB activates caspase-1-mediated apoptosis and IL-1β release necessary for inflammation (132, 170, 171). It does so by directly binding and activating caspase-1 (59). Similarly, the SPI1 T3SS effector SipB of *Salmonella* directly binds and activates caspase-1, resulting in IL-1β and IL-18 release (56). In the reverse of this process, the *Yersinia* T3SS effector YopE inhibits the production of proteolytically active caspase-1, likely through its inhibition of host GTPases (135).

Manipulation of host immune signaling pathways via the T3SSs enables pathogens to modify the cellular and organ environment to their advantage, promoting survival. At the same time, hijacking of the signaling pathways provokes such pathological manifestations as inflammation and apoptosis.

### T3SS and Cells of the Immune System

A consequence of breaching an anatomical barrier, damaging tissues, or triggering host inflammatory signaling is the recruitment and activation of a variety of host immune cells. Resident phagocytes, circulating inflammatory cells, antigen-presenting cells, and lymphocytes have the combined function of identifying, sequestering, and neutralizing invading pathogens. Above, we described some avoidance and resistance strategies used by pathogens to avoid cellular killing by creating specialized environmental niches (A/E lesions and specialized intracellular compartments). In addition to these behaviors, T3SSs are involved in the perturbation of host cellular immune responses. These pathogens exploit T3SS function to select which cells are recruited/produced by the host to combat infection. They also sabotage the function of the recruited cells to pathogenic advantage.

Host immune cells have diverse functions in the control of infection, and their recruitment and coordinated activation are critical for infection control. Pathogens exploit T3SSs to alter this coordination in a variety of ways. Cells responsible for pathogen destruction and processing (antigen-presenting cells), such as neutrophils, macrophages, and dendritic cells (DCs), are critical antibacterial effector cells of the innate immune system.

**Immune cell recruitment.** *Yersinia pestis* selectively targets neutrophils, macrophages, and DCs for the injection of T3SS effectors (93). Through the actions of the effector YopM, *Y. pestis* also depletes the host natural killer (NK) cell population (70). In an analogous way, Phalipon and Sansonetti reported that *Shigella* skews T-cell responses to the Th2 phenotype by down-regulating the production of IL-12 in a T3SS-dependent fashion (116). *Salmonella* is able to overcome the host defense mechanism that immobilizes infected cells and to promote the motility of the infected phagocytes to accelerate its systemic spread from the intestinal lumen (160). This effect is dependent on the interaction of a SPI2 T3SS effector, SrfH/SseI, with the host cell protein TRIP6, which is an adaptor protein in a pathway that stimulates cellular motility. Additional SPI2 effectors are likely to also contribute to this effect. The exploitation of the T3SS to select specific immune cells for destruction or to skew immune cell activation and migration is another mechanism by which T3SS-containing pathogens subvert the host defenses.

**Autophagy and phagocytosis.** If T3SS-containing pathogens are unable to avoid specific host immune cells by preventing their production or recruitment or causing their destruction, they often directly interfere with the antibacterial functions of the cells they encounter. T3SSs are used to interfere with a variety of host cell defenses, such as autophagy and phagolysosomal degradation.

Autophagy was originally described as a mechanism activated in response to nutrient depletion but has since been demonstrated to play an important role as a host innate im-
mune defense (141). This process enables eukaryotic cells to isolate cytoplasmic materials within a membranous compartment and target them for degradation within lysosomes. Autophagy was also shown to promote the presentation of cytosolic antigens via major histocompatibility complex class II and to correlate with the activation of inflammasomes that induce pyroptosis, or inflammatory cell death (24).

*Shigella* actin-based motility is mediated by VirG, which is essential for *Shigella* virulence and dissemination to new hosts. Unfortunately for *Shigella*, however, VirG induces autophagy by binding to Atg5, a host cell autophagy protein. To avoid this host cell detection and elimination mechanism, *Shigella* sequesters IcsB, a T3SS effector, which binds to VirG, thus preventing its interaction with Atg5, avoiding autophagy and promoting *Shigella* survival (108).

In contrast to *Shigella*, *Salmonella* stimulates autophagy in infected macrophages through the action of SipB (55). The advantage of this behavior to *Salmonella* is not well understood, but a striking observation is that all of the pathogens known to trigger pyroptosis also trigger autophagy (141). Regardless of the advantage to the pathogen, however, the cells can retaliate: it was demonstrated that when *Salmonella* is released into the cytosol following the disruption of SCV in a SPI1 T3SS-dependent fashion, host cells can degrade it by autophagy as a means to control infection (7).

Phagocytosis is normally thought of as a host defense mechanism, but this process may provide unintended benefits to the invading pathogen, which can disrupt the phagocytic process and set up residence in the phagocyte, taking advantage of this location as a safe niche and a dissemination mechanism. The ability of *Salmonella* and *Shigella* to induce phagocytosis by nonphagocytic cells and the contribution of this process to virulence are discussed above. Here we review the mechanisms that T3SS-containing pathogens utilize to either avoid phagocytosis by professional phagocytes or infect professional phagocytes by disrupting the normal phagocytic process.

*Salmonella* not only has the capacity to survive in the phagosomes of epithelial cells but is also able to subvert the macrophage phagocytic process by preventing delivery of NADPH oxidase and nitric oxide synthase to the phagosome, thus protecting the resident pathogen from damage by reactive oxygen (36, 156) and nitrogen (16) intermediates. These pathways are dependent on the SPI2 T3SS, consistent with its role in promoting systemic disease.

*Yersinia*, EPEC, and *P. aeruginosa*, on the other hand, have evolved to avoid the harsh environment of the phagosome by interfering with phagocytic uptake (123). Enteric *Yersinia* pathogens and *Y. pestis* resist phagocytosis by both macrophages and neutrophils (124, 157). YopH inhibits the process of phagocytosis by inhibiting the B1-integrin pathway. In neutrophils, it also blocks calcium signaling, which is essential for neutrophil degranulation (115). In macrophages, YopH targets a number of focal adhesion proteins (157). The small GTPases RhoA, Rac, and Cdc42 are inactivated by YopE of *Yersinia*, preventing actin polymerization (2), while the cysteine protease YopT cleaves the isoprenyl lipid moiety of RhoA to depolymerize actin filaments (136). YopO is a serine/threonine kinase that can bind host actin and Rho GTPases, but its contribution to the phagocytic process is still debated (157).

The importance of *Yersinia* avoidance of phagocytosis is demonstrated by the decreased virulence in murine models of mutants lacking various Yop effectors involved in this process (157).

EPEC has a different strategy for blocking phagocytosis: it inhibits phosphatidylinositol 3-kinase function (which is initially activated in response to EPEC infection) in a T3SS-dependent manner, in this way preventing actin polymerization (15).

*Pseudomonas aeruginosa* inhibits phagocytosis by macrophages in vitro via the GTP activity of ExoS, which promotes the inactivation of Rac1 (122). Furthermore, *P. aeruginosa* is able to induce both necrosis and apoptosis in macrophages in a T3SS-dependent manner (50) and to cause neutrophil cytotoxicity, which was also suggested to be mediated by the T3SS (124). Evasion of phagocytosis and cytotoxicity towards professional phagocytes likely contribute to *P. aeruginosa* persistence and dissemination in infected patients.

Overall, the incredibly diverse mechanisms that many pathogens utilize to subvert the host phagocytic process highlight its importance in limiting infection, as well as the importance of phagocytosis subversion as a virulence strategy.

T3SS pathogens manipulate the cells of the immune system in various ways, which ultimately lead to the evasion of clearance and promote persistence and dissemination. The T3SS is vital to all these aspects of pathogenesis, highlighting its central role in the virulence strategy of T3SS pathogens.

**PATHOGENESIS IN SUM: T3SSs IN VIVO**

We have described a series of important T3SS-dependent pathogenic behaviors established in various model infections and cell culture systems. Clearly, T3SSs do not act alone during the pathogenic process and a full complement of virulence factors is required for disease genesis. What, then, is the impact of the T3SS on the infectious process? Moreover, what clinical impact might therapeutics developed to inhibit T3SS function yield? Experimental and bacterial genetic and epidemiological studies provide substantial direct and supportive evidence that T3SSs have become critical to the pathogenic efficiency of the pathogens harboring them.

Although T3SSs do not act in isolation, the impact of their absence on disease pathogenesis is dramatic. The absence of the SPI2-encoded T3SS of *S. enterica* serovar Typhimurium completely abrogates the severity of systemic infection in mice (53, 137) and decreases the severity of intestinal inflammation in mice and cows. In the absence of the proinflammatory stimulus of its two T3SSs, *Salmonella* serovar Typhimurium is totally attenuated in murine and bovine infectious inflammation disease models (19, 20, 47). *Yersinia* species lacking the effectors YopH, YopM, and YopQ are highly attenuated in murine infection (150). *Yersinia enterocolitica*, in which the T3SS component LcrV is unable to activate TL1R2, is attenuated during murine infection (139). Mice infected with T3SS-deficient *C. rodentium*, an A/E pathogen, do not manifest any pathological symptoms caused by wild-type *C. rodentium* infection (46), and deletions of various T3SS effectors of A/E pathogens have been demonstrated to diminish distinct aspects of disease, such as formation of the A/E lesion and disruption of the epithelial barrier (14).
Correlations between the functions of T3SS in vitro and in animal models are predictably recapitulated in human disease. In a retrospective pilot cohort study of endotracheally intubated patients with ventilator-associated Pseudomonas pneumonia, severe (e.g., fatal) illness was associated with the ability of the Pseudomonas isolates to secrete T3SS effectors, in particular the effector ExoU (49). Cystic fibrosis patients were also more likely to have severe acute Pseudomonas infection than chronic infection if they were infected with a T3SS-bearing strain (126). The importance of T3SSs in various in vitro and in vivo models of virulence and their association with severe infection in humans make T3SSs a promising therapeutic target.

THERAPEUTICS: INTERFERENCE WITH T3SS AND VIRULENCE

The T3SS can be viewed as a bacterial organelle that manipulates cell signaling and trafficking, alters cellular morphology, and interferes with the generation of the host immune response (Fig. 2). On the other hand, the T3SS can also be exploited to the host’s advantage. Being unique to the pathogen, it provides a convenient target that can be exploited in designing both therapeutic and prophylactic interventions. Therapeutics specifically targeting the T3SS have special appeal. Unlike the case with conventional antibiotics, targeting a virulence mechanism associated almost exclusively with pathogenic organisms would not perturb the balance of normal flora, resulting in opportunistic infections (e.g., clostridial pseudomembranous colitis). Although resistance to therapeutic interventions may be possible (depending on the mechanism of T3SS inhibition), this would not be a resistance mechanism that would be transferred to non-T3SS-bearing genera of bacteria. Of particular advantage would be the disruption of bacterial virulence mechanisms that are at the core of disease formation, i.e., at the interface of the host and pathogen.

Antibodies against T3SS Proteins

In recent years, we have seen an expansion in the use of antibodies for therapeutic purposes. Passive immunization has been used to counteract the action of various toxins and venoms. It might also prove feasible to use antibodies to treat infection with T3SS-containing pathogens, particularly those such as EHEC, where the use of antibiotics can worsen clinical outcomes.

Monoclonal and polyclonal antibodies raised against T3SS structural proteins have been shown, in vitro and in vivo, to prevent important T3SS-mediated virulence behaviors. In vitro, antibodies raised against the EHEC T3SS structural protein EspA prevent the actin cytoskeletal rearrangements required for formation of the A/E lesion characteristic of T3SS-associated virulence (84). Antibody treatment prevents A/E lesion formation but not filament formation, suggesting that antibodies interfere with effector translocation. Although this inhibition was limited to specific serotypes of EHEC/EPEC, it does suggest that targeting the T3SS apparatus is an appropriate therapeutic intervention to interfere with T3SS-mediated virulence in a broader range of pathogenic E. coli strains.

The IpaD effector of Shigella localizes to the tip of the T3SS needle (27, 131). Although a concrete function for IpaD has not been established, deletions in the C-terminal two-thirds of IpaD have been shown to result in the complete failure of bacterial invasion. In vitro, antibodies to IpaD prevent translocon insertion, Shigella contact-mediated hemolysis of erythrocytes, and Shigella entry into epithelial cells (27, 131). Thus, IpaD has a crucial role in Shigella pathogenesis, and inhibition of its function will likely be very effective in reducing or abolishing Shigella virulence. Moreover, there is significant functional homology between IpaD of Shigella, LcrV of Yersinia, and PcrV of Pseudomonas. In concordance with the observed requirement for IpaD for in vitro T3SS function, immunization against LcrV and PcrV impairs Yersinia and Pseudomonas virulence in vivo.
It has been shown that antibodies to *Yersinia* LcrV (43) and *Pseudomonas* PerV (32, 43) also prevent translocon insertion, while LcrV was recently shown to localize to the T3SS needle tip (101). Anti-PerV antibodies have been shown to be protective in animal models of septic shock. Antibody treatment improved hemodynamic parameters, minimized the extent of tissue injury, and increased host survival (138). Neely et al. (104) also recently demonstrated that intraperitoneal treatment of mice with anti-PerV antibodies provided protection against a lethal challenge with *Pseudomonas* in the setting of a third-degree burn. The improvements were shown to be independent of the Fc receptor, as the administration of the Fab fragment had a protective effect comparable to that of whole immunoglobulin G, indicating that it is the inhibition of T3SS function rather than immunization that likely provides this protection. Antibodies to LcrV have been shown to have a protective effect in animal models of *Y. pestis* infection. All mice treated with monoclonal antibodies to LcrV and challenged with *Y. pestis* survived (61). More recently, monoclonal anti-LcrV antibodies were shown to be protective when administered up to 48 h following *Y. pestis* challenge in both the bubonic and pneumonic plague models, significantly reducing the mortality of mice and prolonging survival (60). Additionally, simultaneous administration of anti-LcrV antibody with an antibody to F1 capsular antigen following *Y. pestis* challenge in a bubonic plague model had a synergistic protective effect compared to administration of either antibody alone.

The therapeutic potential of these antibodies in human infection is clearly worth exploring. Furthermore, the conceptual approach—passive immunization with antibodies targeting T3SS structural proteins—is one that has the potential for broad application to other T3SS-containing pathogens.

**Secreted Effectors as Vaccines**

Attempts are being made to design cheap and effective vaccines against T3SS-containing pathogens, especially because many are endemic to various parts of the world and have tendencies to cause sporadic outbreaks.

LcrV not only is protective against *Y. pestis* during passive immunization but also confers protection to mice immunized with LcrV in models of bubonic and pneumonic plague (52, 85). This may have limited prophylactic potential, however, due to concerns that LcrV is an immunosuppressant in infected hosts (94). Immunization with an alternative T3SS protein, YscF, which facilitates Yop delivery into host cells, was protective in a murine bubonic plague model, suggesting that this type of immunization is experimentally robust for *Yersinia* infection prophylaxis (94, 142).

Because most EHEC outbreaks result from consumption of meat, water, or dairy products contaminated by cattle fecal material, a logical approach to curb the spread of EHEC is to immunize cattle, thus preventing colonization of cattle by EHEC, fecal shedding, and human infections. Some positive results were obtained with the use of secreted proteins of EHEC O157:H7 to immunize cattle and prevent colonization and shedding (118, 155). Therefore, the potential of EHEC secreted proteins as vaccines needs to be evaluated further and specifics that determine the induction of a protective response or the lack thereof determined.

Proteins associated with inclusion membranes of *Chlamydia* have the potential to be presented to the host’s immune system via the major histocompatibility complex class I pathway. The T3SS component LcrE (146) localizes to the inclusion membrane and body (87). Immunization with LcrE was protective in a number of *C. pneumoniae* animal models (130, 146). CopN, another type III secreted *Chlamydia* inclusion membrane protein secreted via the T3SS, was shown to be both immunogenic and protective in mice when administered with *E. coli* heat-labile toxin as an adjuvant (144). However, the extent of protection following immunization with CopN was not as great as that following immunization with LcrE.

Efforts are being made to create a subcellular vaccine that will confer immunity to multiple *Shigella* species to cover a wide range of causative agents of shigellosis. A subunit vaccine consisting of single *Shigella* species lipopolysaccharide and the invasin complex Ipab/C was shown to be protective in homologous challenges in various animal models (154). Oaks and Turbyfill report that a bivalent vaccine incorporating antigens from *S. flexneri* and *Shigella sonnei* was as effective in animal models against challenge with either *S. flexneri* or *S. sonnei* as a monovalent vaccine followed by homologous challenge (107). Antigenic determinants of different *Shigella* species can be combined in this fashion to produce multivalent vaccines conferring immunity to all agents of shigellosis that are clinically prevalent in a particular area.

**T3SS Mutants as Vaccine Strains**

The generation of effective protective immunity to intracellular pathogens often necessitates the presentation of antigens from their unique environmental niches, such as an intracellular compartment, which is best accomplished by the use of live attenuated vaccines. Strains used as live vaccines should have the capacity for intracellular invasion, but at the same time, they should be sufficiently attenuated to prevent tissue damage and long-term persistence. Since T3SSs endow pathogens with the capacity for intracellular invasion and persistence, live vaccines for T3SS-containing pathogens need to be constructed carefully to elicit an appropriate protective immune response while avoiding T3SS-associated damage.

The currently approved live *Salmonella* serovar Typhi vaccine requires the administration of three or four separate doses given every other day, which is a significant practical drawback, especially in developing countries with limited access to medical care (63). An alternative approach that has been explored is to halt *Salmonella*’s persistence by disabling the SPI2 T3SS and limiting its growth in vivo by introducing mutations in essential metabolic pathways. Although it is ineffective as a vaccine for *Salmonella* serovar Typhimurium, a *Salmonella* serovar Typhi strain with mutations in *aroC* (required for aromatic amino acid biosynthesis) and *ssaV* (a structural component of the SPI2 T3SS) was found to be immunogenic in adult volunteers while eliciting only few and mild adverse effects (62, 72).

*Shigella* strains with mutations in various T3SS effectors are potential candidates for vaccine development. A live *virG* mutant (defective for intercellular spreading) and strains that have the *virG* mutation coupled to a mutation in a gene essential for metabolism have been shown to be effective in human
volunteers in terms of both immunogenicity (67, 76–78, 111) and protection (21), although undesired residual cytotoxicity was still observed, prompting further adjustments. To address the residual pathology associated with virG mutant strains while still eliciting an immune response protective against an intracellular pathogen, an alternative strategy was developed by Suzuki et al. (140). A noninvasive Shigella strain with a mutation in ipaB was complemented with inv, an invasin gene of Yersinia (△ipab inv strain). This rendered the △ipab inv strain invasion competent and immunogenic, yet it remained confined to the phagosome and did not induce clinically evident pathology in an animal model (140). As a result, it provides a very attractive alternative to virG mutant vaccine strains as well as a generally interesting paradigm for developing vaccines against intracellular pathogens.

Recombinant antigens of other pathogens and even tumor-associated antigens can be introduced into live attenuated T3SS-expressing carrier strains (by creating effector-antigen fusions) for delivery into the host cell cytosol and efficient T3SS-expressing carrier strains (by creating effector-antigen associated antigens can be introduced into live attenuated vaccines against intracellular pathogens.

Inhibitors of T3SSs

In addition to the exploitation of T3SSs as passive or active immunization targets and for live attenuated vaccines, direct interference with T3SS function has recently become experimentally feasible. Reports of T3SS inhibitors in models of Yersinia and Chlamydia infections have shown promise. Previously identified compounds have been shown to inhibit T3SS function and pathogenesis. Lactoferrin inhibits T3SS-dependent invasion by Shigella by causing degradation of IpaA and IpaB (41, 42). Other novel inhibitors of T3SS function have also been shown to inhibit bacterial virulence. Kauppi and colleagues (68) recently identified a small-molecule inhibitor of T3SS called INP0400. This class of salicylaldehydes inhibits the production of an effective Yersinia T3SS in vitro (106). A set of compounds that function as transcriptional inhibitors of the EPEC T3SS was also identified (38). The therapeutic potential of these compounds against other T3SS-containing pathogens was highlighted by their use in in vitro models of Chlamydia infection. When given at the time of infection, INP0400 inhibited the growth of Chlamydia in infected cells, limiting reticulate body formation and chlamydial fitness (103).

The potential development of these and other T3SS inhibitor compounds will be an area of exciting development in coming years.

T3SSs and Diagnostics

T3SSs are important virulence determinants for all T3SS‐possessing pathogens, and even the presence or absence of particular T3SS effectors was shown to correlate with the progression and outcome of infection in a C. rodentium animal model (159). Consequently, detection of T3SSs in clinical isolates may provide invaluable indications for the management of infected patients.

Detection of the Burkholderia pseudomallei T3SS in clinical specimens by PCR shows promise as a quick diagnostic tool that will enable rapid commencement of appropriate therapy and potentially enhance patient outcomes (35, 97). Similarly, enzyme-linked immunosorbent assay identification of the Pseudomonas T3SS effectors ExoU and ExoT and the T3SS structural components PopD and PcrV can provide fast clues about the type of P. aeruginosa isolate and assist in patient management (86).

The development of similar diagnostic methods for other T3SS-carrying pathogens has the potential to provide significant improvements to patient care and outcomes.

DISCUSSION

It is clear that T3SSs have been adapted to a variety of purposes by bacteria, resulting in the production of disease in infected hosts. The exploitation of T3SSs to establish environmental niches in a variety of host organs, to penetrate barrier defenses, and to provoke or prevent immune responses in the host gives an example of successful T3SS-dependent virulence strategies. It is interesting that opposing strategies (e.g., avoiding or inducing phagocytosis or inducing or inhibiting host immunity) have been employed successfully by pathogens with T3SSs to promote virulence. To debate the relative advantages of the induction of host defenses, such as inflammation, to the host and the T3SS pathogen is a complex subject. It is clear not only that these diverse strategies are successfully executed by these pathogens but also that clinical outcomes associated with infection with these pathogens are worsened by the pathogenic exploitation of T3SSs and that the absence of T3SSs results in decreased disease severity.

Interference with T3SS function by chemical or biological inhibition and vaccination has great potential to reduce the morbidity and mortality associated with infection with these pathogens.

ACKNOWLEDGMENTS

We thank W. Deng, J. Guttman, A. Menendez, E. Arena, and S. Shames for critically reading the manuscript.

This work was supported by operating grants to B.B.F. from the Canadian Institutes of Health Research (CIHR), the Howard Hughes Medical Institute (HHMI), and the Foundation for the NIH as part of the Bill and Melinda Gates Grand Challenge program. B.C. is supported by CIHR and MSFHR studentships. I.S. is supported by a TRID studentship. B.B.F. is a CIHR Distinguished Investigator, an HHMI International Research Scholar, and the University of British Columbia Peter Wall Distinguished Professor.

REFERENCES


